Panbela Therapeutics (PBLA) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 07, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-39468
Entity Registrant Name	Panbela Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2805017
Entity Address, Address Line One	712 Vista Blvd #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		5,127,686
Entity Central Index Key	0001029125
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 907	$ 1,285
Prepaid expenses and other current assets	824	443
Income tax receivable	155	49
Total current assets	1,886	1,777
Other non-current assets	8,742	3,201
Total assets	10,628	4,978
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accounts payable	6,612	2,865
Accrued expenses	1,133	2,993
Accrued interest payable	172	325
Notes payable	0	650
Debt, current portion	1,000	1,000
Total current liabilities	8,917	7,833
Debt, net of current portion	4,194	5,194
Total non current liabilities	4,194	5,194
Total liabilities	13,111	13,027
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of June 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 2,612,038 and 34,761 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	3	0
Treasury Stock at cost; 419 and 0 shares as of September 30, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	106,026	82,286
Accumulated deficit	(109,883)	(91,094)
Accumulated comprehensive income	1,371	759
Total stockholders' (deficit) equity	(2,483)	(8,049)
Total liabilities and stockholders' equity (deficit)	$ 10,628	$ 4,978

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common Stock, Shares, Issued (in shares)	2,996,753	34,761
Common Stock, Shares, Outstanding (in shares)	2,996,334	34,761
Treasury Stock, Common, Shares (in shares)	419	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
General and administrative	$ 1,107	$ 1,294	$ 4,102	$ 4,349
Research and development	6,739	2,329	14,501	24,563
Operating loss	(7,846)	(3,623)	(18,603)	(28,912)
Other income (expense):
Interest income	49	6	114	10
Gain on sale of intellectual property	400	0	400	0
Interest expense	(71)	(87)	(245)	(107)
Other expense	(382)	(754)	(622)	(1,293)
Total other expense	(4)	(835)	(353)	(1,390)
Loss before income tax benefit	(7,850)	(4,458)	(18,956)	(30,302)
Income tax benefit	19	56	167	104
Net loss	(7,831)	(4,402)	(18,789)	(30,198)
Foreign currency translation adjustment	381	727	612	1,240
Comprehensive loss	$ (7,450)	$ (3,675)	$ (18,177)	$ (28,958)
Basic and diluted net loss per share (in dollars per share)	$ (2.69)	$ (257.36)	$ (14.35)	$ (2,255.96)
Weighted average shares outstanding - basic and diluted (in shares)	2,914,600	17,107	1,309,137	13,386

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock Outstanding [Member] Pre-funded Warrants [Member]	Common Stock Outstanding [Member]	Common Stock [Member] Pre-funded Warrants [Member]	Common Stock [Member]	Treasury Stock, Common [Member] Pre-funded Warrants [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member] Pre-funded Warrants [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Pre-funded Warrants [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member] Pre-funded Warrants [Member]	AOCI Attributable to Parent [Member]	Pre-funded Warrants [Member]	Total
Balance (in shares) at Dec. 31, 2021				10,995		0
Balance at Dec. 31, 2021				$ 0		$ 0		$ 66,240		$ (56,160)		$ 133		$ 10,213
Stock-based compensation				0		0		334		0		0		334
Net loss				0		0		0		(3,666)		0		(3,666)
Foreign currency translation adjustment				$ 0		$ 0		0		0		(299)		(299)
RSU's vested, shares (in shares)				4		0
RSU's vested				$ 0		$ 0		0		0		0		0
Balance (in shares) at Mar. 31, 2022				10,999		0
Balance at Mar. 31, 2022				$ 0		$ 0		66,574		(59,826)		(166)		6,582
Balance (in shares) at Dec. 31, 2021				10,995		0
Balance at Dec. 31, 2021				$ 0		$ 0		66,240		(56,160)		133		10,213
Net loss														(30,198)
Foreign currency translation adjustment														1,240
Balance (in shares) at Sep. 30, 2022				17,114		0
Balance at Sep. 30, 2022				$ 0		$ 0		76,707		(86,358)		1,373		(8,278)
Balance (in shares) at Mar. 31, 2022				10,999		0
Balance at Mar. 31, 2022				$ 0		$ 0		66,574		(59,826)		(166)		6,582
Stock-based compensation				0		0		293		0		0		293
Net loss				0		0		0		(22,130)		0		(22,130)
Foreign currency translation adjustment				$ 0		$ 0		0		0		812		812
RSU's vested, shares (in shares)				4		0
RSU's vested				$ 0		$ 0		0		0		0		0
Issuance of common stock - CPP Acquisition, shares (in shares)				6,099		0
Issuance of common stock - CPP Acquisition				$ 0		$ 0		9,605		0		0		9,605
Balance (in shares) at Jun. 30, 2022				17,102		0
Balance at Jun. 30, 2022				$ 0		$ 0		76,472		(81,956)		646		(4,838)
Stock-based compensation				0		0		230		0		0		230
Net loss				0		0		0		(4,402)		0		(4,402)
Foreign currency translation adjustment				$ 0		$ 0		0		0		727		727
Prefunded warrants exercised (in shares)				0		0
Prefunded warrants exercised				$ 0		$ 0		5		0		0		5
Exercise of options, cashless (in shares)				12		0
Exercise of options, cashless				$ 0		$ 0		0		0		0		0
Balance (in shares) at Sep. 30, 2022				17,114		0
Balance at Sep. 30, 2022				$ 0		$ 0		76,707		(86,358)		1,373		(8,278)
Balance (in shares) at Dec. 31, 2022		34,761				0
Balance at Dec. 31, 2022				0		$ 0		82,286		(91,094)		759		(8,049)
Proceeds from sale of Common Stock, shares (in shares)		237,191				0
Proceeds from sale of Common Stock				0		$ 0		15,359		0		0		15,359
Cash paid for fractional shares				0		$ 0		(4)		0		0		(4)
Warrant exchange cashless, shares (in shares)		264,124				0
Warrant exchange cashless				1		$ 0		(1)		0		0		0
Stock-based compensation				0		0		180		0		0		180
Net loss				0		0		0		(5,125)		0		(5,125)
Foreign currency translation adjustment				0		$ 0		0		0		164		164
Balance (in shares) at Mar. 31, 2023		536,076				0
Balance at Mar. 31, 2023				1		$ 0		97,820		(96,219)		923		2,525
Balance (in shares) at Dec. 31, 2022		34,761				0
Balance at Dec. 31, 2022				0		$ 0		82,286		(91,094)		759		(8,049)
Balance (in shares) at Jun. 30, 2023		2,612,038				0
Balance at Jun. 30, 2023				3		$ 0		105,855		(102,052)		990		4,796
Balance (in shares) at Dec. 31, 2022		34,761				0
Balance at Dec. 31, 2022				0		$ 0		82,286		(91,094)		759		(8,049)
Net loss														(18,789)
Foreign currency translation adjustment														$ 612
Exercise of options, cashless (in shares)														0
Balance (in shares) at Sep. 30, 2023		2,996,334				419
Balance at Sep. 30, 2023				3		$ 0		106,026		(109,883)		1,371		$ (2,483)
Balance (in shares) at Mar. 31, 2023		536,076				0
Balance at Mar. 31, 2023				1		$ 0		97,820		(96,219)		923		2,525
Proceeds from sale of Common Stock, shares (in shares)		2,008,881				0
Proceeds from sale of Common Stock				2		$ 0		7,711		0		0		7,713
Cash paid for fractional shares				0		$ 0		(5)		0		0		(5)
Warrant exchange cashless, shares (in shares)		67,694				0
Warrant exchange cashless				0		$ 0		0		0		0		0
Stock-based compensation				0		0		329		0		0		329
Net loss				0		$ 0		0		(5,833)		0		(5,833)
Foreign currency translation adjustment				0				0		0		67		67
Adjustment for fractional shares, shares (in shares)		(613)
Balance (in shares) at Jun. 30, 2023		2,612,038				0
Balance at Jun. 30, 2023				3		$ 0		105,855		(102,052)		990		4,796
Proceeds from sale of Common Stock, shares (in shares)		3,017				0
Proceeds from sale of Common Stock				0		$ 0		3						3
Warrant exchange cashless, shares (in shares)	95,954	120,744			0	0
Warrant exchange cashless			$ 0	0	$ 0	$ 0	$ 0	0	$ 0	0	$ 0	0	$ 0	0
Stock-based compensation				0		0		190		0		0		190
Net loss				0		0		0		(7,831)		0		(7,831)
Foreign currency translation adjustment				0		0		0		0		381		381
Incremental offering costs				0		$ 0		(22)		0		0		(22)
Prefunded warrants exercised (in shares)		165,000				0
Prefunded warrants exercised				0		$ 0		0		0		0		0
Common Stock Repurchased for Treasury Stock (in shares)		(419)
Treasury Stock				0		$ 0		0		0		0		0
Treasury Stock (in shares)						419
Balance (in shares) at Sep. 30, 2023		2,996,334				419
Balance at Sep. 30, 2023				$ 3		$ 0		$ 106,026		$ (109,883)		$ 1,371		$ (2,483)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (18,789)	$ (30,198)
Adjustments to reconcile net loss to net cash used in operating activities:
Write off of in process research and development (IPR&D)	0	17,737
Stock-based compensation	699	857
Non-cash interest expense	172	97
Gain on sale of intellectual property	(400)	0
Changes in operating assets and liabilities:
Income tax receivable	(112)	302
Prepaid expenses and other current assets	(381)	(451)
Other non-current assets	(5,541)	(2,561)
Accounts payable	4,370	5,392
Accrued liabilities	(2,187)	(1,448)
Net cash used in operating activities	(22,169)	(10,273)
Cash flows from investing activities:
Investment in IPR&D	0	(660)
Proceeds from sale of intellectual property	400	0
Cash acquired in merger	0	4
Net cash used in investing activities	400	(656)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of $2.1 million of offering costs	23,052	0
Cash paid for fractional shares	(9)	0
Proceeds from exercise of stock purchase warrants	0	5
Principal payments on notes	(1,650)	0
Net cash provided by financing activities	21,393	5
Effect of exchange rate changes on cash	(2)	(2)
Net change in cash	(378)	(10,926)
Cash and cash equivalents at beginning of period	1,285	11,867
Cash and cash equivalents at end of period	907	941
Supplemental disclosure of cash flow information:
Cash paid during period for interest	398	9
Supplemental disclosure of non-cash transactions:
Fair value of common stock, stock options and stock warrants issued as consideration for asset acquisition	$ 0	$ 9,605

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Proceeds from issuance of common stock and warrants, issuance costs	$ 2.1

Note 1 - Business

Note 1 - Business	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc. (“Panbela”) and its direct wholly owned subsidiaries: Panbela Research, Inc. (“Panbela Research”) Cancer Prevention Pharmaceuticals, Inc. (“CPP”) and Cancer Prevention Pharma (Ireland) Limited exist for the primary purpose of developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. Panbela Therapeutics Pty Ltd is a wholly owned subsidiary of Panbela Research organized under the laws of Australia. Cancer Prevention has two wholly owned dormant subsidiaries: Cancer Prevention Pharma Limited, a United Kingdom entity, and Cancer Prevention Pharmaceuticals, LLC, an Arizona limited liability company. Panbela Therapeutics, Inc., together with its direct and indirect subsidiaries is referred to as “we,” “us,” “our,” and the “Company.” The primary objective of our pipeline is the utilization of pharmacotherapies to reduce or normalize increased disease-associated polyamines using complementary pharmacotherapies. Our lead candidates are ivospemin (SBP-101) for which we have exclusively licensed the worldwide rights from the University of Florida Research Foundation, Inc., Flynpovi™ a combination of eflornithine (CPP-1X) and sulindac and eflornithine (CPP-1X) alone in tablet or sachet form. We have exclusively licensed rights from the Arizona Board of Regents of the University of Arizona to commercialize Flynpovi, and a sublicense agreement to develop and commercialize Flynpovi in North America was terminated by the licensee on April 4, 2023. Reverse stock splits Effective June 1, 2023, Panbela effected a 1-for-30 reverse stock split of its outstanding shares of common stock. Effective January 13, 2023, Panbela effected a 1-for-40 reverse stock split of its outstanding shares of common stock. Unless specifically provided otherwise herein, all share and per share amounts of our common stock presented have been retroactively adjusted to reflect the reverse stock splits. See Note 7 for more information.

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (the “FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures. We have incurred losses of $109.9 million since our inception in 2011. For the nine months ended September 30, 2023, we incurred a net loss of $18.8 million. We also incurred negative cash flows from operating activities of approximately $22.2 million for this period. As we continue to pursue development activities and seek commercialization, we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. We generated approximately $21.4 million positive cash flows from financing activities related to proceeds from the sale of common stock, pre-funded warrants, and warrants, partially offset by the payments made on two promissory notes. As of September 30, 2023, we had cash of approximately $0.9 million, working capital deficit of $7.0 million, (working capital is defined as current assets less current liabilities), and stockholders’ deficit of $2.5 million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities. The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed In January of 2022, the Company announced the opening of a global randomized Phase II/III clinical trial, which is being conducted in the United States, Europe and Asia Pacific (APAC). The Company does not expect any disruption to the conduct of this new clinical trial associated with COVID-19. The trial is reliant on adequate supply of gemcitabine and Abraxane (nab-paclitaxel) which can be subject to supply shortages.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022, was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form 10-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan On June 21, 2023, the Company completed a registered public offering of common stock, pre-funded warrants and warrants which resulted in net proceeds of approximately $7.7 million. On January 30, 2023, the Company completed a registered public offering of common stock, pre-funded warrants and warrants which resulted in net proceeds of approximately $13.8 million. Also, in the first quarter of 2023, the Company received net proceeds of approximately $1.6 million from the sale of common stock via the Company’s ATM Program (See Note 7). No sales occurred under the ATM Program during the second quarter of 2023. We need to raise additional capital to support our current business plans. We may seek to raise additional funds through various sources, such as equity and debt financing, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data were not positive or economic and market conditions deteriorate. Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our product candidates ivospemin, Flynpovi and eflornithine in the United States or other markets and ultimately our ability to market and sell product candidates. If we are unable to obtain additional financing when needed, if our clinical trials are not successful or if we are unable to obtain marketing approval, we would not be able to continue as a going concern and would be forced to cease operations and liquidate our company. There can be no assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses. Research and development costs Research and development costs include expenses incurred in the conduct of our clinical trials; for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of drug product for our product candidates for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our product candidates; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain licensed intellectual property. We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. The cost to secure certain third-party drug product for the clinical trials, which is often paid for in advance of delivery, is charged to research and development when it is received and available to be shipped to clinical sites. Research and development costs for 2022 include IPR&D. This asset was acquired from the security holders of CPP and written off to research and development immediately subsequent to the asset acquisition. All material CRO contracts are terminable by us upon written notice, and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license. Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based on historical company share price volatility. The assumed dividend yield is zero Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd, are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the nine-month periods ended September 30, 2023 and 2022, any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential. Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect is anti-dilutive or reduce a net loss per share. The Company’s potentially dilutive shares, which include outstanding common stock options, and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. The following table sets forth the potential shares of common stock that were not included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of the dates indicated: September 30, 2023 2022 Employee and non-employee stock options 13,455 3,352 Common stock issuable under common stock purchase warrants 4,068,826 4,538 4,082,281 7,890

Note 6 - Notes Payable

Note 6 - Notes Payable	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes Payable Sucampo promissory note As of September 30, 2023, CPP had a balance outstanding of approximately $5.4 million for principal and interest under an amended and restated promissory note (the “Sucampo Note). The note was issued with an initial principal amount of approximately $6.2 million in favor of Sucampo GmbH dated as of June 15, 2022. The principal balance outstanding as of September 30, 2023 of approximately $5.2 million under the Sucampo Note bears simple interest at a rate of 5% per annum. All unpaid principal, together with any then unpaid and accrued interest is payable as follows: (i) $1.0 million, plus all interest accrued but unpaid on or before each of January 31, 2024, January 31, 2025, and January 31, 2026; and (ii) all remaining principal plus accrued but unpaid interest on or before January 31, 2027. On February 1, 2023, Panbela paid the balance due of $1.0 million plus accrued and unpaid interest of approximately $295,000. As of September 30, 2023, the Company was current in all payments due under the Sucampo Note and the accrued and unpaid interest on this note was approximately $172,000. Panbela has agreed to guarantee CPP’s payment obligations under the Sucampo Note pursuant to a Guaranty dated as of June 15, 2022. Tillotts promissory note As of December 31, 2022, CPP had a balance outstanding of approximately $0.7 million representing principal and interest under an amended promissory note issued with an initial principal amount of approximately $650,000 in favor of Tillotts Pharma AG. The principal balance and accrued and unpaid interest were paid in full on January 31, 2023.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	7. Stockholders Equity Public offering of common stock and warrants June 2023 On June 21, 2023, the Company completed a registered public offering and issued an aggregate of 586,000 shares of its common stock, pre-funded warrants to purchase up to an aggregate of 1,684,000 shares of common stock at an exercise price of $0.001 per share and warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at an exercise price of $3.75 per share. The securities were issued for a combined offering price of $3.75 per share of common stock and warrants to purchase two shares, or $3.749 per pre-funded warrant and warrants to purchase two Of the remaining warrants, warrants to purchase 2,270,000 shares of common stock, have an alternative cashless exercise provision pursuant to which the holder may provide notice and receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 0.24. This feature became available on June 28, 2023 and as of June 30, 2023 no As of the same date warrants to purchase up to an aggregate of 4,036,900 shares of common stock remained outstanding with an exercise price of $3.75 per shares, of which warrants to purchase 1,766,900 were eligible for alternative cashless exercise. Public offering of common stock and warrants January 2023 On January 30, 2023, the Company completed a registered public offering and issued an aggregate of 161,407 shares of its common stock, pre-funded warrants to purchase up to an aggregate of 61,090 shares of common stock at an exercise price of $0.001 per share and warrants to purchase up to an aggregate of 444.999 shares of its common stock at an exercise price as adjusted, of $2.239 per share. The securities were issued for a combined offering price of $67.50 per share of common stock and warrants to purchase two two All of the pre-funded warrants were exercised by February 3, 2023. The remaining warrants have an alternative cashless exercise provision pursuant to which the holder may provide notice and receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 0.75. This feature became available on March 1, 2023 and as of as of September 30, 2023, 331,824 shares of common stock had been issued for warrants to purchase 442,434 shares. Warrants to purchase 2,566 shares of common stock remained outstanding with an exercise price as adjusted, of $2.239 per share. At-the-market program We are party to a Sales Agreement dated July 29, 2022, pursuant to which Roth Capital Partners, LLC (the “Agent”) may sell shares of the Company’s common stock having an aggregate gross sales price of up to $8.4 million, from time to time, through an “at-the-market” equity offering program (the “ATM Program”). Under the Sales Agreement, Roth is entitled to a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the ATM Program. During January 2023, the Company sold 14,694 shares of common stock under the ATM Program for approximately $1.6 million in gross proceeds. During September 2023, the Company sold 3,017 shares of common stock under the ATM program for approximately $3,900 in gross proceeds. In connection with the warrant transactions that occurred subsequent to the end of the period, the Company is restricted from selling under the ATM Program until at least May 2, 2024 (See Note 10). Reverse stock splits On May 25, 2023, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split within a range of a ratio of one-for-five (1:5) up to a ratio of one-for-one hundred (1:100). On June 1, 2023, the Company's Board of Directors approved the implementation of the reverse stock split of the Company's Common Stock at a ratio of one-for-thirty (1:30). As a result of the reverse stock split, every thirty No On November 29, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-forty (1:40). On January 13, 2023, the Company's Board of Directors approved the implementation of the reverse stock split of the Company's Common Stock. As a result of the reverse stock split, every forty No Shares reserved The following shares of common stock were reserved for future issuance as of the date indicated: September 30, 2023 Stock options outstanding 13,455 Shares available for grant under equity incentive plan - Warrants outstanding 4,068,826 4,082,281

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	8. Stock-based Compensation 2016 Omnibus Incentive Plan The Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan (the “2016 Plan”) was adopted by our Board of Directors in March 2016 and approved by our stockholders in May 2016. The 2016 Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2016 Plan at no less than the fair market value of the underlying common stock as of the date of grant. Options granted under the 2016 Plan have a maximum term of ten no 2011 Stock Option Plan Our Board of Directors ceased making awards under the Panbela Therapeutics, Inc. 2011 Stock Option Plan (the “2011 Plan”) upon the original receipt of stockholder approval for the 2016 Plan in May 2016. Awards outstanding under the 2011 Plan remain outstanding in accordance with and pursuant to the terms thereof. As of September 30, 2023, options to purchase 171 shares of common stock remained outstanding under the 2011 Plan. The weighted average exercise price is $3,721.58 and the average remaining life is approximately 1.3 years. CPP s 2010 Equity Incentive Plan The Company has assumed all remaining rights and obligations with respect to CPP’s 2010 Equity Incentive Plan (the “CPP Plan”) through the issuance of replacement options. As of September 30, 2023, options to purchase 1,230 shares of common stock remained outstanding under the CPP Plan, with a weighted average exercise price of $361.56 per share, and the average remaining contractual life was 6.8 years. Stock-based compensation expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2023 vest based upon time-based and performance conditions. There was approximately $0.2 million unamortized stock-based compensation expense related to options granted to employees, directors, and consultants as of September 30, 2023. The unamortized expense will be recognized over the next 12 months. Stock-based compensation expense for each of the periods presented is as follows (in thousands): Nine Months Ended September 30, 2023 2022 General and Administrative $ 554 $ 697 Research and Development 145 160 $ 699 $ 857 Details of options granted, exercised, cancelled, or forfeited during the nine months ended September 30, 2023 follows: Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2023 3,287 $ 4,369 $ - Granted 10,240 15 Exercised - - Cancelled (72 ) 1,424 Forfeitures or expirations - - Balance at September 30, 2023 13,455 $ 1,071 $ - Information about stock options outstanding, vested and expected to vest as of September 30, 2023 is as follows: Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $15 10,240 9.50 $ 15 1,662 9.50 $264 1,150 7.26 $ 264 1,150 7.26 $1,764 - $3,540 582 5.01 $ 3,215 569 4.94 $3,810 - $4,908 498 5.57 $ 4,493 398 5.08 $5,004 - $7,320 428 6.14 $ 6,102 428 6.14 $9,720 - $18,120 557 4.81 $ 12,987 557 4.81 Totals 13,455 8.66 $ 1,071 4,764 7.19 Assumptions used to calculate the fair market value of options granted in the nine month period ended September 30, 2023 include: 2023 Common stock fair value $15.00 Risk-free interest rate 3.59% - 3.60% Expected dividend yield Expected Option life 5.08 - 5.50 Expected stock price volatility 131.0% - 138.0%

Note 9 - Gain on Sale of Intell

Note 9 - Gain on Sale of Intellectual Property	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	9. Gain on Sale of Intellectual Property On July 17, 2023, the Company divested certain rights, titles and interests in its eflornithine pediatric neuroblastoma program. Under the terms of the agreement, the Company is entitled to receive up to approximately $9.5 million in non-dilutive funding in exchange for the sale of these assets. An initial payment of $400,000 was received by the Company at the time of closing, remaining payments will be receivable if the acquiring company successfully completes certain milestones related to clinical development, regulatory approval and commercial sales. At the time of closing, the successful completion of these milestones is not probable and the Company did not recognize these future payments on the date of the sale as they did not have any realized or realizable value. It was determined that the contract was not with a customer and did not represent the sale of a business and therefore the initial payment was recognized as a gain on sale of intellectual property which was reflected in other income during the three months ended September 30, 2023.

Note 10 - Subsequent Events

Note 10 - Subsequent Events	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	10. Subsequent Events On November 2, 2023, the Company entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of its existing warrants to purchase shares of common stock (the “Existing Warrants”), pursuant to which the Holders agreed to exercise for cash their Existing Warrants to purchase 2,130,000 shares of the Company’s common stock, in the aggregate, at a reduced exercise price of $0.78 per share, in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”) on substantially the same terms as the Existing Warrants described below, to purchase up to 4,260,000 shares of the Company’s common stock (the “Inducement Warrant Shares”) and a cash payment of $0.125 per Existing Warrant Share which was paid in full upon the exercise of the Existing Warrants. The Company received aggregate gross proceeds of approximately $1.9 million from the exercise of the Existing Warrants by the Holders and the sale of the Inducement Warrants. The Company incurred $115,659 in investment banking fees relating to the transaction, in addition to reimbursement for certain expenses. The Company has agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrants Shares issued or issuable upon the exercise of the Inducement Warrants (the “Resale Registration Statement”) within twenty (20) calendar days of the date of the Inducement Letters. In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until the Company receives stockholder approval. The Company also has agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until one year from the date of the Inducement Letters, other than an at-the-market offering, which may be effected after the date that is six months from the date of the Inducement Letters.

Insider Trading Arrangement

Insider Trading Arrangement	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Material Terms of Trading Arrangement [Text Block]	Item 5. Other Information. During the three 30, 2023, 408(a) S-K.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our clinical trials; for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of drug product for our product candidates for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our product candidates; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain licensed intellectual property. We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. The cost to secure certain third-party drug product for the clinical trials, which is often paid for in advance of delivery, is charged to research and development when it is received and available to be shipped to clinical sites. Research and development costs for 2022 include IPR&D. This asset was acquired from the security holders of CPP and written off to research and development immediately subsequent to the asset acquisition. All material CRO contracts are terminable by us upon written notice, and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license.
Share-Based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based on historical company share price volatility. The assumed dividend yield is zero
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd, are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the nine-month periods ended September 30, 2023 and 2022, any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect is anti-dilutive or reduce a net loss per share. The Company’s potentially dilutive shares, which include outstanding common stock options, and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. The following table sets forth the potential shares of common stock that were not included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of the dates indicated: September 30, 2023 2022 Employee and non-employee stock options 13,455 3,352 Common stock issuable under common stock purchase warrants 4,068,826 4,538 4,082,281 7,890

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2023 2022 Employee and non-employee stock options 13,455 3,352 Common stock issuable under common stock purchase warrants 4,068,826 4,538 4,082,281 7,890

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	September 30, 2023 Stock options outstanding 13,455 Shares available for grant under equity incentive plan - Warrants outstanding 4,068,826 4,082,281

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Nine Months Ended September 30, 2023 2022 General and Administrative $ 554 $ 697 Research and Development 145 160 $ 699 $ 857
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2023 3,287 $ 4,369 $ - Granted 10,240 15 Exercised - - Cancelled (72 ) 1,424 Forfeitures or expirations - - Balance at September 30, 2023 13,455 $ 1,071 $ -
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $15 10,240 9.50 $ 15 1,662 9.50 $264 1,150 7.26 $ 264 1,150 7.26 $1,764 - $3,540 582 5.01 $ 3,215 569 4.94 $3,810 - $4,908 498 5.57 $ 4,493 398 5.08 $5,004 - $7,320 428 6.14 $ 6,102 428 6.14 $9,720 - $18,120 557 4.81 $ 12,987 557 4.81 Totals 13,455 8.66 $ 1,071 4,764 7.19
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 Common stock fair value $15.00 Risk-free interest rate 3.59% - 3.60% Expected dividend yield Expected Option life 5.08 - 5.50 Expected stock price volatility 131.0% - 138.0%

Note 1 - Business (Details Text

Note 1 - Business (Details Textual)				12 Months Ended
	Jun. 01, 2023	May 31, 2023	Jan. 13, 2023	Dec. 31, 2022
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30	30	40	40

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Retained Earnings (Accumulated Deficit)	$ 109,883						$ 109,883		$ 91,094
Net Income (Loss) Attributable to Parent	7,831	$ 5,833	$ 5,125	$ 4,402	$ 22,130	$ 3,666	18,789	$ 30,198
Net Cash Provided by (Used in) Operating Activities							22,169	10,273
Net Cash Provided by (Used in) Financing Activities							21,393	5
Cash and Cash Equivalents, at Carrying Value	907						907		1,285
Working Capital	7,000						7,000
Equity, Attributable to Parent	$ (2,483)	$ 4,796	$ 2,525	$ (8,278)	$ (4,838)	$ 6,582	$ (2,483)	$ (8,278)	$ (8,049)	$ 10,213

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($)			1 Months Ended		3 Months Ended
	Jun. 21, 2023	Jan. 30, 2023	Sep. 30, 2023	Jan. 31, 2023	Mar. 31, 2023
Registered Public Offering [Member]
Proceeds from Issuance or Sale of Equity	$ 7,700,000	$ 13,800,000
ATM Program [Member]
Proceeds from Issuance of Common Stock			$ 3,900	$ 1,600,000	$ 1,600,000

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies (Details Textual) Pure in Thousands	9 Months Ended
	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%

Note 5 - Summary of Significa_4

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Anti-dilutive securities (in shares)	4,082,281	7,890
Share-Based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	13,455	3,352
Warrant [Member]
Anti-dilutive securities (in shares)	4,068,826	4,538

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details Textual) - USD ($)	Feb. 01, 2023	Jun. 15, 2022	Sep. 30, 2023	Dec. 31, 2022
Sucampo Note [Member]
Long-Term Debt			$ 5,400,000
Debt Instrument, Face Amount		$ 6,200,000
Long-Term Debt, Gross			5,200,000
Debt Instrument, Interest Rate, Stated Percentage		5%
Debt Instrument, Periodic Payment		$ 1,000,000
Repayments of Long-Term Debt	$ 1,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities	$ 295,000
Interest Payable			$ 172,000
Tillotts Note [Member]
Long-Term Debt				$ 700,000
Debt Instrument, Face Amount				$ 650,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual)								1 Months Ended		2 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 21, 2023 USD ($) $ / shares shares	Jun. 01, 2023	May 31, 2023	May 25, 2023	Jan. 30, 2023 USD ($) $ / shares shares	Jan. 13, 2023 shares	Jul. 29, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares shares	Jan. 31, 2023 USD ($) shares	Sep. 30, 2023 $ / shares shares	Mar. 31, 2023 USD ($)	Jun. 30, 2023 shares	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022	Aug. 04, 2023 $ / shares shares
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		30	30			40								40
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)						0							0
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				5
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				100
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,684,000				61,090
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.001				$ 0.001
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,540,000				444.999			2,566		2,566			2,566		4,036,900
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.75				$ 2.239			$ 2.239		$ 2.239			$ 2.239		$ 3.75
Class of Warrants or Rights, Eligible for Cashless Exercise	2,270,000														1,766,900
Class of Warrants or Rights, Cashless Exchange Feature (in shares)	0.24				0.75
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)										120,744
Class of Warrant or Right, Exercised During Period										503,100			442,434
Stock Issued During Period, Shares, Warrants Exercised													331,824
Registered Public Offering [Member]
Stock Issued During Period, Shares, New Issues	586,000				161,407
Units Issued, Stock and Warrant, Price Per Share | $ / shares	$ 3.75				$ 67.50
Units Issued, Warrant and Warrant, Price Per Unit | $ / shares	$ 3.749				$ 67.47
Units Issued, Warrant and Warrant, Warrant Per Unit	2				2
Proceeds from Issuance or Sale of Equity | $	$ 7,700,000				$ 13,800,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)												0
Units Issued, Stock and Warrant, Number of Warrants Per Unit					2
ATM Program [Member]
Stock Issued During Period, Shares, New Issues								3,017	14,694
Equity Offering, Maximum Amount | $							$ 8,400,000
Equity Offering, Commission, Percentage of Gross Proceeds							3%
Proceeds from Issuance of Common Stock | $								$ 3,900	$ 1,600,000		$ 1,600,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Sep. 30, 2023 shares
Shares reserved (in shares)	4,082,281
Share-Based Payment Arrangement, Option [Member]
Shares reserved (in shares)	13,455
Shares Available for Grant Under Equity Incentive Plan [Member]
Shares reserved (in shares)	0
Warrant [Member]
Shares reserved (in shares)	4,068,826

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	13,455	3,287
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 1,071
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 0.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	12 months
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	12,054
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	0
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 1,105.88
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	171
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 3,721.58
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 3 months 18 days
CPP's 2010 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	1,230
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price	$ 361.56
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 9 months 18 days

Note 8 - Stock-based Compensa_4

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based compensation expense	$ 699	$ 857
General and Administrative Expense [Member]
Share-based compensation expense	554	697
Research and Development Expense [Member]
Share-based compensation expense	$ 145	$ 160

Note 8 - Stock-based Compensa_5

Note 8 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Balance, shares available for grant (in shares)	3,287
Balance, weighted average exercise price per share (in dollars per share)	$ 4,369
Aggregate intrinsic value	$ 0	$ 0
Granted, shares available for grant (in shares)	10,240
Granted, weighted average exercise price per share (in dollars per share)	$ 15
Excercised, shares available for grant (in shares)	0
Exercised, weighted average exercise price per share (in dollars per share)	$ 0
Cancelled, shares available for grant (in shares)	(72)
Forfeitures or expirations (in shares)	0
Forfeitures or expirations, weighted average exercise price per share (in dollars per share)	$ 0
Balance, shares available for grant (in shares)	13,455
Balance, weighted average exercise price per share (in dollars per share)	$ 1,071

Note 8 - Stock-based Compensa_6

Note 8 - Stock-based Compensation - Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Options outstanding (in shares) | shares	13,455
Options outstanding, weighted average remaining contractual life (Year)	8 years 7 months 28 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1,071
Options exercisable (in shares) | shares	4,764
Options excercisable, weighted average remaining contractual life (Year)	7 years 2 months 8 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15
Options outstanding (in shares) | shares	10,240
Options outstanding, weighted average remaining contractual life (Year)	9 years 6 months
Options outstanding, weighted average exercise price (in dollars per share)	$ 15
Options exercisable (in shares) | shares	1,662
Options excercisable, weighted average remaining contractual life (Year)	9 years 6 months
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 264
Options outstanding (in shares) | shares	1,150
Options outstanding, weighted average remaining contractual life (Year)	7 years 3 months 3 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 264
Options exercisable (in shares) | shares	1,150
Options excercisable, weighted average remaining contractual life (Year)	7 years 3 months 3 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 1,764
Options outstanding (in shares) | shares	582
Options outstanding, weighted average remaining contractual life (Year)	5 years 3 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3,215
Options exercisable (in shares) | shares	569
Options excercisable, weighted average remaining contractual life (Year)	4 years 11 months 8 days
Per share exercise price, upper limit (in dollars per share)	$ 3,540
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 3,810
Options outstanding (in shares) | shares	498
Options outstanding, weighted average remaining contractual life (Year)	5 years 6 months 25 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 4,493
Options exercisable (in shares) | shares	398
Options excercisable, weighted average remaining contractual life (Year)	5 years 29 days
Per share exercise price, upper limit (in dollars per share)	$ 4,908
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 5,004
Options outstanding (in shares) | shares	428
Options outstanding, weighted average remaining contractual life (Year)	6 years 1 month 20 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6,102
Options exercisable (in shares) | shares	428
Options excercisable, weighted average remaining contractual life (Year)	6 years 1 month 20 days
Per share exercise price, upper limit (in dollars per share)	$ 7,320
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9,720
Options outstanding (in shares) | shares	557
Options outstanding, weighted average remaining contractual life (Year)	4 years 9 months 21 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 12,987
Options exercisable (in shares) | shares	557
Options excercisable, weighted average remaining contractual life (Year)	4 years 9 months 21 days
Per share exercise price, upper limit (in dollars per share)	$ 18,120

Note 8 - Stock-based Compensa_7

Note 8 - Stock-based Compensation - Fair Market Value Assumptions of Options Granted (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares
Common stock fair value (in dollars per share)	$ 15
Minimum [Member]
Risk-free interest rate	3.59%
Expected Option life (Year)	5 years 29 days
Expected stock price volatility	131%
Maximum [Member]
Risk-free interest rate	3.60%
Expected Option life (Year)	5 years 6 months
Expected stock price volatility	138%

Note 9 - Gain on Sale of Inte_2

Note 9 - Gain on Sale of Intellectual Property (Details Textual)	Jul. 17, 2023 USD ($)
Proceeds from Divestiture of Businesses and Interests in Affiliates	$ 400,000
Maximum [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 9,500,000

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Nov. 02, 2023 USD ($) $ / shares shares
Proceeds from Warrants Exercise and Issuance of New Warrants | $	$ 1,900,000
Investment Banking Fee | $	$ 115,659
Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	2,130,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.78
Inducement Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	4,260,000
Cash Payment on Exercise of Warrants, Price Per Share | $ / shares	$ 0.125

Insider Trading Arrangement (De

Insider Trading Arrangement (Details Textual)	3 Months Ended
	Sep. 30, 2023
Rule 10b5-1 Arrangement Adopted [Flag]	False
Non-Rule 10b5-1 Arrangement Adopted [Flag]	False
Rule 10b5-1 Arrangement Terminated [Flag]	False
Non-Rule 10b5-1 Arrangement Terminated [Flag]	False